Pfizer Inc. (PFE)
Is This Ultra-High Yield Dividend Stock a Steal at a 19% Discount?
Key Points in This Article: Pfizer's (PFE) stock has fallen 19% from its 52-week high and 50% over three years due to declining COVID-19 product sales and patent cliff concerns.
Pfizer's Turnaround Has Truly Started (Earnings Update)
Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting, signaling a successful turnaround is underway. Key drugs like Vyndaqel, Paxlovid, and Lobrena drove impressive sales growth, offsetting headwinds from the Inflation Reduction Act and patent disputes. The valuation remains highly attractive, with PFE trading at a significant discount to peers and offering a robust 7.28% dividend yield.
Pfizer Q2: Dividends Speak Louder Than EPS
At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. However, given the strong EPS headwinds and large EPS uncertainties, I suggest investors focus on other profit indicators such as dividends and buybacks. Its latest dividend declaration keeps showing pressured growth.
Pfizer CEO talks lowering drug prices, tariffs, and earnings
Pfizer (PFE) topped second quarter expectations, but looming Trump-era pharmaceutical tariffs remain a concern. Pfizer CEO Albert Bourla joins Market Domination to discuss the company's earnings results and cost-cutting efforts.
Pfizer Inc. (PFE) Q2 2025 Earnings Call Transcript
Pfizer Inc. (NYSE:PFE ) Q2 2025 Earnings Conference Call August 5, 2025 10:00 AM ET Company Participants Aamir Malik - Corporate Participant Albert Bourla - Chairman of the Board & CEO Alexandre de Germay - Executive VP & Chief International Commercial Officer Andrew Simon Baum - Chief Strategy & Innovation Officer, Executive VP Chris Boshoff - Chief Scientific Officer and President of Research & Development David M. Denton - CFO & Executive VP Francesca M.
Pfizer Q2 Earnings Review: Upside At Last As CEO Prepares For Trump Policy Battle
Pfizer delivered a strong Q2 2025, beating revenue and EPS estimates, raising EPS guidance, and maintaining its attractive dividend yield above 7%. Product portfolio strength is evident, with growth in Primary Care, Specialty Care, and Oncology, but looming patent expiries and regulatory risks persist. Management's financial discipline is improving, with cost savings, debt management, and a focus on extracting value from recent M&A deals.
Pfizer Q2 Earnings Beat Estimates, Oncology Drives Top-Line Growth
PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost cuts.
Pfizer Stock Pops on Q2 Beat-and-Raise
The shares of Pfizer Inc (NYSE:PFE) were last seen up 4.9% to trade at $24.4, after the pharmaceutical giant's second-quarter results beat expectations.
Here's What Key Metrics Tell Us About Pfizer (PFE) Q2 Earnings
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Buy Pfizer Stock At $24?
Pfizer (NYSE: PFE) has recently reported impressive second-quarter results, with both revenue and earnings exceeding analyst expectations. The company disclosed adjusted earnings of $0.78 per share on $14.65 billion in revenue, surpassing consensus estimates of $0.58 per share and $13.56 billion.
Pfizer raises profit forecast after Q2 earnings beat estimates
Pfizer Inc (NYSE:PFE, ETR:PFE) raised its full-year profit outlook on Tuesday after posting better-than-expected second-quarter earnings, driven by strong sales of key drugs including Comirnaty and Paxlovid. The drugmaker reported adjusted earnings of $0.78 per share, beating analysts' average estimate of $0.58, according to LSEG data.
Pfizer (PFE) Surpasses Q2 Earnings and Revenue Estimates
Pfizer (PFE) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.6 per share a year ago.
